All patients were followed until death or at least 1 month.Ĩ9% of 90 patients experienced a full reversal of the effect of Pradaxa within 4 hours of administration.1Department of Neuroscience, IRCCS – Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy 2Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK 3Department of Internal Medicine and Medical Specialties, Sapienza-University of Rome, Rome, Italy 4Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, ItalyĪbstract: Use of non-vitamin K antagonist oral anticoagulants is spreading in the real world. The treatment was given to two groups of patients Group A, patients with serious bleeding, and Group B, patients who required an urgent procedure. The study treatment consists of 2 infusions of 2.5 g IV Praxbind given no more than 15 mins apart. Researchers plan to recruit 300 patients in 400 centers in 38 countries. The RE-VERSE AD trial is an ongoing multicenter, prospective cohort study that looks at patients who are chronic users of Pradaxa. There was an immediate reduction (within minutes) of the effect of Pradaxa after administration of 5 g of Praxbind. Praxbind was studied in three randomized trials in 283 healthy volunteers taking Pradaxa. The FDA granted accelerated approval for Praxbind to be used in patients taking Pradaxa who need a reversal of its effects for emergency surgical procedures or life-threatening or uncontrolled bleeding. This prevents Pradaxa from blocking thrombin so the body can resume its normal clotting mechanism. Praxbind is a monoclonal antibody fragment that binds Pradaxa 350 times more strongly than thrombin. Pradaxa works by binding thrombin, the blood’s natural clotting agent, thus preventing clots from forming. Praxbind ( idarucizumab ) is an injectable drug that reverses the anticoagulation (blood thinning) effect of Pradaxa (dabigatran). What is Praxbind and its mechanism of action? Medication Class: humanized monoclonal antibody fragment

Idarucizumab mechanism of action